Short answer
4D Molecular Therapeutics, Inc. (FDMT) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). First-quarter 2026 results cover the three months ended March 31, 2026.
4D Molecular Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- First-quarter 2026 results cover the three months ended March 31, 2026
- Press release includes financial results, operational highlights, and upcoming milestones
- Disclosure furnished under Item 2.02, directing investors to the accompanying exhibit for detailed figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other 4D Molecular Therapeutics, Inc. 8-K filings
Get the next FDMT 8-K as it lands
Follow FDMT for push alerts, or ask the research agent what this filing means.